Drug Development
Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Inc.'s HyBryte(TM) shows promising treatment success in early-stage cutaneous T-cell lymphoma, offering hope for patients with limited options.
Lantern Pharma Unveils AI Module to Enhance Cancer Combination Therapies Development
Lantern Pharma introduces an AI-powered module to streamline the creation of targeted cancer combination therapies, promising to cut development time and costs significantly.
NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
Creative Biolabs Enhances Antibacterial Drug Development with Integrated Mechanism and Pharmacokinetic Strategies
Creative Biolabs is revolutionizing antibacterial drug development by integrating mechanism identification and pharmacokinetic modeling early in the process to mitigate risks and enhance success rates.
Kairos Pharma Ltd. Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105
Kairos Pharma Ltd. announces favorable interim safety results from its Phase 2 trial of ENV-105 for metastatic castration-resistant prostate cancer, marking a significant step forward in cancer therapy.
Sino Biological Introduces ProPure™ Endotoxin-Free Proteins, Enhancing Research and Therapeutic Development
Sino Biological US, Inc. launches ProPure™, a line of ultra-pure, endotoxin-free recombinant proteins produced in the USA, setting a new industry standard for research and therapeutic applications.
Creative Biolabs Advances ADC Therapy with Precision Toxin Design and Pharmacokinetic Analysis
Creative Biolabs highlights the intricate balance and design behind ADC therapy, emphasizing the importance of toxin precision and pharmacokinetic studies for effective cancer treatment.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15
Silo Pharma Inc. is on the verge of receiving crucial preclinical study results for SPC-15, a potential breakthrough in PTSD treatment, marking a significant step towards addressing a long-unmet medical need.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
Nutriband Inc. Advances in Opioid Safety with AVERSA(TM) Fentanyl Milestone
Nutriband Inc. achieves a significant milestone in the development of AVERSA(TM) Fentanyl, an abuse-deterrent opioid, marking progress in addressing the global opioid crisis.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix Inc. is developing SGX943, a novel immunotherapy that enhances the body's immune response to combat bacterial infections, addressing the critical challenge of antibiotic resistance.
Lantern Pharma's AI Platform Shows Promise in Lung Cancer Treatment
Lantern Pharma's AI-driven drug development platform, RADR®, has demonstrated significant potential in treating non-small cell lung cancer, with a Phase 2 trial patient achieving a complete response after previous treatments failed.
NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) explores the potential of its lead product candidate, TPI 287, in treating Glioblastoma Multiforme (GBM) and future metastatic tumor indications, as discussed by Dr. Erin Dunbar in a recent Virtual Investor KOL Connect segment.
Creative Biolabs Advances mRNA Therapeutics with Comprehensive Solutions
Creative Biolabs is enhancing the development of mRNA therapies, offering innovative solutions that address key challenges in stability, delivery, and scalability, pivotal for treatments ranging from HIV to cancer.
Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement
Nutriband Inc.'s price target was raised to $15 following the successful commercial manufacturing and scale-up of its AVERSA Fentanyl abuse-deterrent transdermal patch, marking a significant step towards clinical trials and potential market entry.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Lantern Pharma Inc. (NASDAQ: LTRN) has reported a significant clinical outcome in its Phase 2 HARMONIC(TM) trial, showcasing the potential of its LP-300 treatment in combination with standard chemotherapy for never-smoker patients with advanced non-small cell lung cancer (NSCLC), marking a pivotal moment in oncology treatment.
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development
Nutriband Inc. showcases a 63% year-over-year revenue increase in Q1 2025 and progresses in developing AVERSA Fentanyl, aiming to introduce the first abuse-deterrent opioid patch globally.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Creative Biolabs Advances Microbiome-Based Drug Development with Enhanced LBP Analytics
Creative Biolabs has introduced an advanced microbial service platform to streamline the development of microbiome-based drugs, addressing key challenges in strain characterization, contaminant detection, and formulation stability.
Alfa Cytology Launches PARP Inhibitors Development Services for Advanced Cancer Treatment
Alfa Cytology has introduced comprehensive development services for PARP inhibitors, offering a promising avenue for more precise and personalized cancer treatments, particularly for cancers with genetic mutations like BRCA1 and BRCA2.
FDA's Accelerated Launch of AI Tool Elsa Sparks Transparency and Oversight Concerns
The FDA's early release of its AI tool, Elsa, aims to enhance efficiency in drug development processes but has ignited debates over the lack of transparency and potential oversight issues.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
Soligenix Inc. (SNGX) Reports Promising HyBryte Results for CTCL Treatment
Interim data from a Soligenix Inc. study highlights HyBryte's potential as a safer, faster-acting treatment for cutaneous T-cell lymphoma, offering new hope for patients with this chronic condition.
Telomir Pharmaceuticals Advances Telomere-Targeting Drug, Seeks Strategic Partnerships
Telomir Pharmaceuticals is preparing to submit an Investigational New Drug (IND) application for Telomir-1, a potential breakthrough small molecule targeting aging mechanisms, with plans to explore strategic collaborations at the BIO International Convention 2025.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.